Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 + FOLFIRI in Second-Line Neuroendocrine Neoplasm
NCT05879055Phase 2Active, not recruiting
- Sponsor
- Biotheus
- Start
- May 2023
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in Neuroendocrine neoplasm (NEN), sponsored by Biotheus. Started May 2023; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT05879055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879055.